Atlantic Fish Company is developing cultivated seafood via cellular agriculture and is headquartered in Raleigh-Durham, North Carolina.
Qatch Technologies is focused on creating innovative tools to assess the injectability and manufacturability of biopharmaceutical products. The company has developed a proprietary pre-screening technology that integrates microfluidics and acoustics, allowing for the precise measurement of viscosity using minimal liquid volumes. This advanced technology enables biopharmaceutical researchers to identify suitable injectable formulations at early stages of development, thereby streamlining the process of selecting optimal molecules for further study. By addressing potential manufacturing challenges related to viscosity, Qatch Technologies aims to enhance the efficiency and effectiveness of drug development in the biopharmaceutical sector.
Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.
InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.
Amalgent Therapeutics is developing combination drugs that dramatically reduce the doses required for effective analgesia. The company was founded in 2020 and is headquartered in Chapel Hill, North Carolina, United States.
InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.
Lacuna Medical
Debt Financing in 2023
Lacuna Medical has created a 3D shape catheter that is more resistant to catheter failure. The 3D shape protection uses memory shape to the protect the proximal holes of the catheter.
North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.
North Carolina Central University (NCCU), established in 1910, is a historically black college located in Durham, North Carolina. It has built a strong reputation for its commitment to academic excellence, research, and cultural awareness. NCCU offers over 100 programs across nearly 30 academic departments, providing both undergraduate and graduate degrees. Notable offerings include unique programs such as a master’s degree in Jazz Studies and a bachelor’s degree in Apparel Design, alongside joint graduate programs in law and business. The university actively promotes diversity, welcoming students of all races and ethnicities, and provides various financial aid options, including institutional scholarships and need-based government programs. With a focus on preparing students for success in a global marketplace, NCCU continues to play a vital role in higher education and community development.
Belhaven Biopharma is focused on developing life-saving medications for the treatment of anaphylaxis. The company specializes in the scale-up and production of clinical trial materials, as well as the preparation and filing of Investigational New Drug applications. It is currently conducting a pilot human clinical trial for its innovative dry powder intranasal epinephrine, which is designed to offer a convenient, safe, and rapid treatment option during emergency situations. By developing a portfolio of dry powder nasal medications, Belhaven Biopharma aims to enhance patient access to timely treatment in critical moments.
North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.
The University of North Carolina at Greensboro, also known as UNCG and UNC Greensboro, is a public coeducational and research university in Greensboro in North Carolina in the United States of America, and it is a constituent institution of the system of the University of North Carolina. However, the University of North Carolina at Greensboro is a stand-alone university and awards its own degrees like all members of the system of the University of North Carolina . The Southern Association of Colleges and Schools Commission on Colleges accredits the University of North Carolina at Greensboro to award baccalaureate, masters, specialist, and doctoral degrees.
The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.
Sigma Xi is an international honor society for scientists and engineers. It also provides grants annually to promising young researchers and sponsors a variety of programs supporting ethics in research, science, and engineering education.
University of North Carolina at Asheville is a co-educational, four year, public liberal arts university.
Coprata is a digital health and technology company that offers innovative solutions for monitoring gut health through stool analysis and artificial intelligence. By enabling hands-free stool sampling and automated monitoring of bowel movements during regular toilet use, Coprata provides individuals with valuable insights into their gut health. This service allows users to track the effects of their lifestyle choices and receive early warnings about potential changes in their gut health. The platform aims to facilitate the detection and management of both acute and chronic gastrointestinal diseases, as well as infectious diseases. Additionally, Coprata is focused on developing non-invasive methods for health monitoring that seamlessly integrate into daily routines, ultimately enhancing personalized wellness and health management.
Enzerna Biosciences is a biotechnology company based in Morrisville, North Carolina, specializing in gene therapy solutions. The company focuses on addressing nucleotide expansion disorders by utilizing Artificial Site-Specific RNA Endonucleases (ASREs). These engineered proteins are designed to target and eliminate toxic RNA molecules responsible for these disorders, offering a potential long-term curative approach. Enzerna's innovative RNA editing technology and related products aim to provide effective treatments for genetic diseases.
Oncotect is a Raleigh-based biotech startup focused on the early detection of cancer risks in dogs through a novel urine-based screening test. The company has developed a patent-pending in-vitro diagnostic platform that utilizes proprietary technology alongside the olfactory receptors of C. elegans to identify cancerous volatile metabolites in dog urine. This innovative method provides a non-invasive, convenient, and affordable approach to multi-cancer screening, making it the only test of its kind available for dogs. By enabling dog owners to detect potential cancer risks early, Oncotect aims to improve canine health outcomes and enhance the ability to manage cancer in pets.
UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.
Plakous Therapeutics, a human biologics company that specializes in restorative and regenerative healing. The company advances in regenerative healing by manufacturing bio-therapeutics from the post-delivery human placenta. It establishes a safe and effective therapeutic platform to promote and sustain healing using the placental cytokines and growth factors that orchestrate fetal development and also allow the body to heal itself. Seth Tomblyn and Scott Washburn co-founded the company in 2016 and Headquartered in Winston Salem, North Carolina.
Plakous Therapeutics, a human biologics company that specializes in restorative and regenerative healing. The company advances in regenerative healing by manufacturing bio-therapeutics from the post-delivery human placenta. It establishes a safe and effective therapeutic platform to promote and sustain healing using the placental cytokines and growth factors that orchestrate fetal development and also allow the body to heal itself. Seth Tomblyn and Scott Washburn co-founded the company in 2016 and Headquartered in Winston Salem, North Carolina.
Renaissance Fiber produces high-quality fiber from domestically sourced industrial hemp using proprietary methods that are clean (Ecologically Invisible™), inexpensive, and scalable. Our material is suitable for a wide range of applications in textiles and technical fibers.
Coprata is a digital health and technology company that offers innovative solutions for monitoring gut health through stool analysis and artificial intelligence. By enabling hands-free stool sampling and automated monitoring of bowel movements during regular toilet use, Coprata provides individuals with valuable insights into their gut health. This service allows users to track the effects of their lifestyle choices and receive early warnings about potential changes in their gut health. The platform aims to facilitate the detection and management of both acute and chronic gastrointestinal diseases, as well as infectious diseases. Additionally, Coprata is focused on developing non-invasive methods for health monitoring that seamlessly integrate into daily routines, ultimately enhancing personalized wellness and health management.
Plakous Therapeutics, a human biologics company that specializes in restorative and regenerative healing. The company advances in regenerative healing by manufacturing bio-therapeutics from the post-delivery human placenta. It establishes a safe and effective therapeutic platform to promote and sustain healing using the placental cytokines and growth factors that orchestrate fetal development and also allow the body to heal itself. Seth Tomblyn and Scott Washburn co-founded the company in 2016 and Headquartered in Winston Salem, North Carolina.
Kepley BioSystems is focused on developing innovative technologies aimed at addressing significant challenges in both marine and healthcare sectors. The company offers ocean restorative technology designed to combat the depletion of wild fish populations, promoting sustainable practices in marine ecosystems. Additionally, Kepley BioSystems is advancing life science solutions that provide accurate methods for testing dangerous endotoxins. Their platform focuses on healthcare innovations, specifically in the detection of blood-borne pathogens, enabling physicians to deliver rapid and sensitive diagnostics for bloodstream infections. Through these efforts, Kepley BioSystems aims to contribute to environmental sustainability and improve health outcomes.
The Company is focused on the commercialization of its first oncology application: treatment of advanced hepatocellular carcinoma. It has completed a phase II study, which shows effectiveness as well as excellent tolerability, even in previously treated patients with severely impaired liver function. See less
North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.
The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.
Appalachian State University in Boone, North Carolina, offers rigorous academics and a rich assortment of cultural activities in a scenic environment at the foot of the beautiful Appalachians. Bachelor’s and graduate degrees are awarded in more than 170 areas of study. Undergraduate majors include: * Actuarial Science * Archaeology * Dance Studies * Geography * Music Education * Nursing * Social Work * Theatre Arts In addition to its substantial academics, App State has a large number of cultural arts activities, which include Concerts, Literary Readings and Theatre productions. There is also a Summer Arts festival, a glass gallery, a sculpture competition and a performing arts series. Since Appalachian is a selective school, admissions to Appalachian are competitive, with the average student having a GPAof 3.94 and an average SAT of 1141. Financial aid is provided through institutional scholarships, which are awarded based on extracurricular involvement or academic merit. Students may also apply for federal aid sources such as Pell grants and loans.
EncepHeal Therapeutics is a Therapeutics company. EncepHeal Therapeutics is Non-addictive prescription substitutes have been a very popular solution for people addicted to drugs like tobacco and opioids. EncepHeal Therapeutics is creating medications to help the 2.5 million cocaine and methamphetamine addicts have a similar option.
North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.
RainBIO is a pioneering company in the field of ocular gene therapy, specifically targeting corneal blindness. The company has developed an innovative adeno-associated virus (AAV) vector gene therapy designed to reverse and prevent blindness by directly improving corneal cellular function. This therapy aims to assist patients who are at risk of losing their eyesight due to various ocular conditions, enabling them to maintain or restore their vision. RainBIO's approach represents a significant advancement in the treatment of corneal diseases, offering hope to individuals facing the threat of blindness.
Belhaven Biopharma is focused on developing life-saving medications for the treatment of anaphylaxis. The company specializes in the scale-up and production of clinical trial materials, as well as the preparation and filing of Investigational New Drug applications. It is currently conducting a pilot human clinical trial for its innovative dry powder intranasal epinephrine, which is designed to offer a convenient, safe, and rapid treatment option during emergency situations. By developing a portfolio of dry powder nasal medications, Belhaven Biopharma aims to enhance patient access to timely treatment in critical moments.
East Carolina University (ECU) is a public doctoral/research institution located in Greenville, North Carolina. Founded in 1907 and formerly known as East Carolina Teachers College, it became East Carolina University in 1951. ECU offers a wide range of undergraduate, graduate, and doctoral programs across various fields, including health sciences, medicine, nursing, music, fine arts, communication, technology, and business. The university is distinguished by its Brody School of Medicine, which ranks highly for its emphasis on primary care and rural medicine. Additionally, ECU provides distance education courses to cater to a diverse student population. The East Carolina University Foundation, established in 1963, manages an endowment fund aimed at enhancing the university's academic programs, research activities, and overall student experience.
NabGen, Inc. is an NC based biotech company developing an antibody suppression platform with broad applications. Their initial focus is solving a long-standing limitation in gene therapy: patient derived anti-drug antibodies that form a barrier to delivery of AAV based therapeutics. NabGen’s primary goal is to ensure all patients benefit from gene therapy treatments by enabling successful administration to those with pre-existing vector immunity and generating redosing opportunities that are currently unavailable. Using a novel protein-based approach as a universal antibody suppressant, NabGen’s technology broadly targets and blocks all antibody types, including neutralizing antibodies (NAbs) against any therapeutic vector, thus enabling successful vector mediated gene delivery without immunocompromising patients.
UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.
Helixomer is a company focused on designing and creating functional nucleic acid nanostructures for applications in human health. The company specializes in developing innovative solutions such as RNA-based anticoagulants and their specific reversal agents, utilizing a thrombin inhibitor and antidote. By advancing the field of nucleic acid technology, Helixomer aims to provide effective alternatives to traditional therapies, including potential antibody replacements.
Drive Therapeutics is a new biotechnology company that strives to improve treatment for retinal diseases.
Apie Therapeutics specializes in the development and commercialization of innovative drug therapies that target the Apelin Receptor biased agonist, focusing on the Apelinergic System. The company aims to pioneer anti-fibrosis therapies that address microvascular diseases by leveraging the Apelin/APJ signaling pathway, which plays a crucial role in protective and post-injury repair mechanisms. By activating this signaling path in endothelial organs, Apie Therapeutics seeks to enhance treatment options for patients suffering from pulmonary, cardiovascular, and metabolic diseases, ultimately improving their quality of life.
CasTag Biosciences is focused on advancing cell biology and regenerative medicine through innovative tools that enhance the analysis of endogenous proteins. By developing adeno-associated virus kits, the company aims to expedite scientific discovery and empower researchers to investigate novel genes across various experimental models. Utilizing a unique two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering, CasTag's products enable the modification of entire panels of proteins within cells and tissues, thereby facilitating a deeper understanding of biological processes.
Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.
North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.
Chiesi USA is a pharmaceuticals company that specializes in research and development services aimed at addressing respiratory, inflammatory, and critical care diseases. The company is dedicated to the discovery, development, and commercialization of products specifically designed to treat conditions such as asthma and other critical care ailments. By focusing on the regulation of the body's inflammatory response, Chiesi USA aims to enhance therapeutic options within the pharmaceutical industry.
Lindy Biosciences, LLC is a development-stage company based in Durham, North Carolina, specializing in protein-based therapeutic formulations. Utilizing a technology known as microglassification, the company gently removes a significant portion of water from solutions of proteins and other biologics, resulting in solid, spherical, amorphous microbeads. These microbeads create stable, dense particles of therapeutic proteins suitable for various applications, including high-concentration injectable suspensions, encapsulation for controlled release, and long-term storage. Established in 2016, Lindy Biosciences aims to provide innovative solutions for the formulation of protein therapeutics, addressing the needs of medical researchers in developing advanced therapeutic options.
Locus Biosciences is focused on developing a CRISPR-engineered platform aimed at transforming the treatment of bacterial diseases. This innovative platform integrates CRISPR-Cas3 technology with bacteriophage, which are viruses that specifically target and eliminate pathogenic bacteria. By leveraging this combination, Locus Biosciences enables healthcare providers to initiate treatment more rapidly, ultimately leading to improved medical outcomes for patients. The company's approach is designed to offer a precise and effective solution for addressing bacterial infections.
Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.
Higgs Boson Health (HBH), a leading digital health company empowering all people undergoing acute interventional or surgical procedures to live healthier lives.
PRA International, a prominent global contract research organization, specializes in providing outsourced clinical development and data solution services to the pharmaceutical and biotechnology industries. The company operates through two main segments: Clinical Research and Data Solutions. The Clinical Research segment encompasses a wide range of services, including clinical trial management, regulatory affairs, biostatistics, and quality assurance, as well as early development services for Phase I and Phase IIa studies. The Data Solutions segment offers various analytical and consulting services, enabling clients to access and interpret vital data through technology-enabled products. With over 17,000 employees and operations in more than 90 offices worldwide, PRA International has played a crucial role in advancing drug development, having participated in over 3,800 clinical trials and supporting pivotal studies that led to the regulatory approval of numerous products. The organization has also partnered with The Leukemia & Lymphoma Society to develop treatments for childhood leukemia. Founded in 1976 and headquartered in Raleigh, North Carolina, PRA International is recognized for its commitment to excellence in clinical research.
Virokine Therapeutics is a Biotechnology company.
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
BiomedInnovations is a medical device company that makes precision air and fluid flow devices, including products for lung ventilators and ex-vivo organ and tissue perfusion.
Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, particularly those with perinatal brain injury. Its lead drug aims to promote the regeneration of myelin-producing oligodendrocytes and reverse white matter injury in premature infants. By providing effective treatments for all babies at risk of brain injury, Tellus Therapeutics seeks to enhance neurodevelopmental outcomes for these vulnerable children.
North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.
East Carolina University (ECU) is a public doctoral/research institution located in Greenville, North Carolina. Founded in 1907 and formerly known as East Carolina Teachers College, it became East Carolina University in 1951. ECU offers a wide range of undergraduate, graduate, and doctoral programs across various fields, including health sciences, medicine, nursing, music, fine arts, communication, technology, and business. The university is distinguished by its Brody School of Medicine, which ranks highly for its emphasis on primary care and rural medicine. Additionally, ECU provides distance education courses to cater to a diverse student population. The East Carolina University Foundation, established in 1963, manages an endowment fund aimed at enhancing the university's academic programs, research activities, and overall student experience.
The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.
UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.
Cereius, Inc. is a pre-clinical stage biotechnology company based in Durham, North Carolina, founded in 2017. The company specializes in developing small-molecule therapies aimed at treating brain metastasis, particularly in patients with HER2-positive breast cancer. Cereius employs innovative radiolabeling chemistries that enhance the uptake and retention of radionuclides in target tumors while reducing absorption in normal tissues. This approach significantly improves the therapeutic index and diagnostic contrast of targeting agents, enabling medical practitioners to more effectively treat solid tumor brain metastasis and potentially increase patient survival rates.
Duke BioRepository & Precision Pathology Center (BRPC), Duke’s largest human tissue biobank. BRPC stores samples from consented patients for use in research.
InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.
Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.
Arrevus, Inc. is a clinical-stage biotechnology company based in Raleigh, North Carolina, focused on developing innovative therapies for orphan diseases, particularly those complicated by antibiotic resistance. Incorporated in 2015, Arrevus has a pipeline that includes several promising candidates: ARV-1801, an oral formulation of fusidic acid aimed at treating pulmonary exacerbations in cystic fibrosis; ARV-1907, an inhaled version of fusidic acid designed for treating persistent staphylococcus aureus lung infections in cystic fibrosis patients; ARV-1502, an engineered inhibitor of bacterial DnaK for cancer treatment; and ARV-1802, a leptin receptor antagonist also targeting cancer. The company is dedicated to addressing critical health issues where existing treatments are limited, particularly in cases where antibiotic resistance poses significant clinical challenges. Through its research, Arrevus aims to enhance treatment options for serious, life-threatening conditions, ultimately improving patient outcomes and quality of life.
Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals, specifically targeting skin diseases such as atopic dermatitis and osteoarthritis. Founded in 2019 and located in Chapel Hill, North Carolina, the company aims to improve the health and well-being of pets by utilizing a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects commonly associated with systemic medications. Through its efforts, Aniluxx Biotechnology seeks to provide effective and user-friendly treatment options for dogs, cats, and horses suffering from various skin conditions.
IMMvention Therapeutix is a biotechnology company focused on developing innovative small molecule pan-inflammasome inhibitors aimed at treating inflammatory diseases. The company utilizes a platform technology that leverages biodegradable biopolymeric nano/micro-particles to enhance the immune response. IMMvention Therapeutix specifically targets auto-inflammatory conditions, such as rheumatoid arthritis, osteoarthritis, gout, and Alzheimer's disease, addressing significant unmet medical needs. Its disease-modifying therapies work by inhibiting inflammation triggered by inflammasomes, which are responsible for activating inflammatory responses. In addition to its primary focus, the company also seeks to improve clinical outcomes for patients with other inflammatory conditions, including neuroinflammatory, renal, and metabolic diseases, thereby contributing to the treatment of autoimmune disorders.
Emergo Therapeutics is a pharmaceutical startup that develops treatment options for flu-like illnesses. It is focused on developing drugs to modulate inflammatory cytokines and improve the functioning of the immune system in various potential indications, starting with infectious diseases. Emergo’s therapeutic interventions are focused on reducing the production of inflammatory cytokines from mast cells. Emergo is headquartered in Durham, North Carolina.
AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.
Redbud Labs is a microfluidic chip manufacturer. They are pioneering a new category of consumable components with MXR, the world’s first fully modular microfluidic mixer. World-class biotechnology firms use MXR to boost assay performance.Redbud Labs leverages MEMS technology conceived in Professor Richard Superfine’s research group at the University of North Carolina at Chapel Hill. They combine their breakthrough platform with deep scientific expertise to develop elegant solutions to the toughest microfluidic challenges.
TregTherapeutics is a preclinical stage company focused on the treatment and possible cure of multiple sclerosis. The T lymphocyte is a key component in the acquired immune system, and a subset of T cells, the T-regulator cell (known as the Treg), plays an instrumental role in the control and regulation of the immune response. Named in recognition of the vital functions this cell executes, TregTherapeutics Inc. is focused on developing a tolerogenic vaccine for the treatment and possible cure of multiple sclerosis. The corporation is a North Carolina-based preclinical-stage company whose proprietary technology is based upon an exclusive license granted by East Carolina University. The technology is a transformative platform that utilizes a novel vaccine approach that harnesses the power of Tregs to dramatically alter patient outcomes in response to autoimmune disease.
Dualogics is a biotechnology company located at the University of North Carolina at Chapel Hill, specializing in the development of bispecific antibodies aimed at treating oncology and autoimmune diseases. Utilizing a proprietary technology, the company engineers new antibody therapeutics, diagnostics, and research tools, resulting in bispecific antibody products that offer enhanced properties compared to traditional methods. Dualogics aims to collaborate with both academic institutions and industry partners to advance a range of multifunctional therapies and reagents, ultimately seeking to improve treatment options for patients affected by these conditions.
InnAVasc Medical specializes in the development of medical devices designed to improve vascular access for hemodialysis. The company focuses on enhancing existing synthetic vascular grafts to ensure safer and more efficient access for dialysis procedures. Their products aim to prevent needle cannulation injuries and improve graft access safety, thus helping healthcare providers minimize the risks of adverse events and device failures that can occur with repeated vascular access. Additionally, InnAVasc addresses the needs of home hemodialysis and immediate access, contributing to overall patient safety and care in the dialysis process.
Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.
Cereius, Inc. is a pre-clinical stage biotechnology company based in Durham, North Carolina, founded in 2017. The company specializes in developing small-molecule therapies aimed at treating brain metastasis, particularly in patients with HER2-positive breast cancer. Cereius employs innovative radiolabeling chemistries that enhance the uptake and retention of radionuclides in target tumors while reducing absorption in normal tissues. This approach significantly improves the therapeutic index and diagnostic contrast of targeting agents, enabling medical practitioners to more effectively treat solid tumor brain metastasis and potentially increase patient survival rates.
Locus Biosciences is focused on developing a CRISPR-engineered platform aimed at transforming the treatment of bacterial diseases. This innovative platform integrates CRISPR-Cas3 technology with bacteriophage, which are viruses that specifically target and eliminate pathogenic bacteria. By leveraging this combination, Locus Biosciences enables healthcare providers to initiate treatment more rapidly, ultimately leading to improved medical outcomes for patients. The company's approach is designed to offer a precise and effective solution for addressing bacterial infections.
Locus Biosciences is focused on developing a CRISPR-engineered platform aimed at transforming the treatment of bacterial diseases. This innovative platform integrates CRISPR-Cas3 technology with bacteriophage, which are viruses that specifically target and eliminate pathogenic bacteria. By leveraging this combination, Locus Biosciences enables healthcare providers to initiate treatment more rapidly, ultimately leading to improved medical outcomes for patients. The company's approach is designed to offer a precise and effective solution for addressing bacterial infections.
Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.
Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.
OneFul Health is an e-pharmacy for personalized therapies, combining 3-7 prescription drugs into one small capsule or gel packet. Provide telemedicine physician network connections and home tests for biomarkers and genomic poly-scores to formulate combination treatments with reduced adverse side effects and improved adherence. Founded in 2013 as Panacea BioMatx Inc as a healthcare technology development company. It spun-off Panaceutics.com in 2021, then renamed to OneFul Health to commercialize D2C and B2B personlized pharmaceutical products. Owns accredited pharmacy facilities as its regulatory platform in nine states.
Jenken Biosciences is a specialty pharmaceutical company dedicated to the development and commercialization of first-in-class small molecules as TLR4 antagonists. TLR4 (Toll-Like Receptor 4) is a transmembrane protein, a key mediator of inflammatory responses, and a member of TLR family which are mainstays of the innate immune system. Recently, TLR4 has attracted considerable clinical attention and is the subject of a number of published studies on inflammation associated with chronic liver disease, inflammatory bowel disease, cancer, and diabetes, as well as organ damage to the kidney and lung. The Company's drug development strategy is to reduce time-to-market and to lower risk and development costs by re-profiling approved drugs. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapies of chronic liver disease, inflammatory bowel disease, rheumatoid arthritis, and diabetes, as well as organ damage to the kidney and the lung.